1342811-02-2

Basic information

• Product Name: C₁₆H₃₂O₃Si
• Synonyms: C₁₆H₃₂O₃Si
• CAS NO: 1342811-02-2
• Molecular Weight: 300.514
• Mol File: 1342811-02-2.mol

Chemical Properties

• CAS DataBase Reference: C₁₆H₃₂O₃Si(CAS DataBase Reference)
• NIST Chemistry Reference: C₁₆H₃₂O₃Si(1342811-02-2)
• EPA Substance Registry System: C₁₆H₃₂O₃Si(1342811-02-2)

Safety Data

• Hazardous Substances Data: 1342811-02-2(Hazardous Substances Data)

Upstream product

• 80522-42-5 triisopropylsilyl trifluoromethanesulfonate 
• 1352615-11-2 ethyl 4-triisopropylsilyloxycyclohexylcarboxylate 
• 3618-04-0 4-hydroxycyclohexyl carboxylic acid ethyl ester 
• 13154-24-0 triisopropylsilyl chloride 

Downstream Products

• 1342811-03-3 C₁₇H₃₄O₃Si 
• 412293-43-7 tert-butyl N-(1-methyl-4-oxo-cyclohexyl)carbamate 
• 792913-83-8 tert-butyl N-(4-hydroxy-1-methylcyclohexyl)carbamate 
• 1342811-04-4 C₂₁H₄₃NO₃Si 
• 1342811-05-5 C₁₇H₂₅BrN₄O₂ 

Relevant articles and documents

Liquid crystal compound, a liquid crystal display element and a liquid crystal composition

A liquid crystal compound having a high stability to heat, light or the like, a wide temperature range of a nematic phase, a small viscosity, a suitable optical anisotropy, a large elastic constant K33, a large negative dielectric anisotropy and an excellent compatibility with other liquid crystal compounds. Also, a liquid crystal composition having characteristics similar to these of the compound. Additionally, a liquid crystal display device having a short response time, low electric power consumption, a low driving voltage, a large contrast and a wide temperature range in which the device can be used. The compound is a 2,3-difluorobenzene derivative (1) having a combination of a cyclohexane ring, a cyclohexene ring or a benzene ring phenyl and a butene bonding group. The liquid crystal composition includes this compound, and the liquid crystal display device contains this composition.

Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins

The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system. The present invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the preparation of medicaments for treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins. A method of treating or preventing diseases or conditions associated with amyloid and/or amyloid-like proteins is also disclosed.